In an interview with PharmExec Associate Editor Don Tracy, Jingsong Wang discusses Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033.
Jingsong Wang, Chairman of Nona Biosciences, discusses Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033, an innovative antibody-drug conjugate (ADC) targeting MSLN, a key antigen in various solid tumors. Wang believes that the partnership will significantly advance Nona's Harbour Mice® platform and ADC ecosystem.
Dr. Jingsong Wang founded Nona Biosciences in 2022, and he is currently Chairman of Nona Biosciences. Dr. Wang has more than 20 years of extensive experience, achievement and leadership in pharmaceutical research and development. Prior to establishing Nona, Dr. Wang founded Harbour BioMed and served as its Chairman and CEO. Before that, he served as Head of China R&D and Head of Translational Medicine, Asia Pacific, at Sanofi. He is a former attending physician and clinical fellow at Harvard Medical School. Dr. Wang received his Ph.D.in Molecular Pharmacology from China Pharmaceutical University and completed a Molecular Immunology Research Fellowship at the Harvard School of Public Health.
The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.
Listen to this podcast on
